TranæusA.A long-term study of a bicarbonate/lactate-based peritoneal dialysis solution—clinical benefits. The Bicarbonate/Lactate Study Group.Perit Dial Int2000; 20: 516–23.
2.
MactierR.A., SprosenT.S., GokalR., WilliamsP.F., LindberghM., NaikR.B.Bicarbonate and bicarbonate/lactate peritoneal dialysis solutions for the treatment of infusion pain.Kidney Int Suppl1998; 53: 1061–7.
3.
RippeB., SimonsenO., HeimbürgerO., ChristenssonA., HaraldssonB., StelinG.Long-term clinical effects of a peritoneal dialysis fluid with less glucose degradation products.Kidney Int2001; 59: 348–57.
WilliamsJ.D., TopleyN., CraigK.J., MackenzieR.K., PischetsriederM., LageC.The Euro-Balance Trial: the effect of a new biocompatible peritoneal dialysis fluid (Balance) on the peritoneal membrane.Kidney Int2004; 66: 408–18.
6.
McIntyreC.W.Update on peritoneal dialysis solutions.Kidney Int2007; 71: 486–90.
7.
JörresA.Novel peritoneal dialysis solutions—what are the clinical implications?Blood Purif2012; 33: 153–9. [Erratum in: Blood Purif 2012; 34:17]
8.
FanS.L., PileT., PunzalanS., RafteryM.J., YaqoobM.M.Randomized controlled study of biocompatible peritoneal dialysis solutions: effect on residual renal function.Kidney Int2008; 73: 200–6.
9.
JohnsonD.W., BrownF.G., ClarkeM., BoudvilleN., EliasT.J., FooM.W.Effects of biocompatible versus standard fluid on peritoneal dialysis outcomes.J Am Soc Nephrol2012; 23: 1097–107.
10.
DaviesS.J., WoodrowG., DonovanK., PlumJ., WilliamsP., JohanssonA.C.Icodextrin improves the fluid status of peritoneal dialysis patients: results of a double-blind randomized controlled trial.J Am Soc Nephrol2003; 14: 2338–44.
11.
KoppleJ.D., BernardD., MessanaJ., SwartzR., BergströmJ., LindholmB.Treatment of malnourished CAPD patients with an amino acid based dialysate.Kidney Int1995; 47: 1148–57.
12.
RippeB., VenturoliD.Peritoneal transport kinetics with amino acid-based and glucose-based peritoneal dialysis solutions.Perit Dial Int2007; 27: 518–22.
13.
le PooleC.Y., WeltenA.G., WeijmerM.C., ValentijnR.M., van IttersumF.J., ter WeeP.M.Initiating CAPD with a regimen low in glucose and glucose degradation products, with icodextrin and amino acids (NEPP) is safe and efficacious.Perit Dial Int2005; 25(Suppl 3): S64–8.
14.
FreidaP., WilkieM., JenkinsS., DallasF., IssadB.The contribution of combined crystalloid and colloid osmosis to fluid and sodium management in peritoneal dialysis.Kidney Int Suppl2008; (108): S102–11.
15.
BonominiM., PandolfiA., Di LiberatoL., Di SilvestreS., CnopsY., Di TomoP.l-Carnitine is an osmotic agent suitable for peritoneal dialysis.Kidney Int2011; 80: 645–54.
16.
RippeB., ZakariaE.R., CarlssonO.Theoretical analysis of osmotic agents in peritoneal dialysis. What size is an ideal osmotic agent?Perit Dial Int1996; 16(Suppl 1): S97–103.
17.
RippeB., LevinL.Computer simulations of ultrafiltration profiles for an icodextrin-based peritoneal fluid in CAPD.Kidney Int2000; 57: 2546–56.
18.
MendelsonA., GuanQ., ChafeevaI., Da RozaG., KizhakkedathuJ., DuC.Hyperbranched polyglycerol is an efficacious and biocompatible novel osmotic agent in a rodent model of peritoneal dialysis.Perit Dial Int2013; 33: 15–27.
19.
KainthanR.K., BrooksD.E.In vivo biological evaluation of high molecular weight hyperbranched polyglycerols.Biomaterials2007; 28: 4779–87.
